CHARLOTTE, N.C., Dec. 22, 2014 /PRNewswire/ -- Deloitte
Corporate Finance LLC ("DCF") acted as exclusive financial advisor
to Diamondback Drugs of Delaware,
LLC ("Diamondback Drugs" or "Company"), a portfolio company of
Sheridan Legacy Group, LLC ("Sheridan
Legacy"), in its sale to Tailwind Capital. Diamondback
Drugs is a national specialty veterinary pharmacy operating
throughout the United States.
Sheridan Legacy invested in
Diamondback Drugs in 2012, when it partnered with the Company's
founders. Dave Vorhoff,
managing director for Deloitte Corporate Finance LLC, along with
other DCF professionals advised Diamondback in the 2012 transaction
with Sheridan Legacy while at a
predecessor firm.
"We were pleased to execute on a number of strategic initiatives
under the leadership of Sheridan
Legacy and look forward to our partnership with Tailwind
Capital," said Michael Blaire, CEO
of Diamondback Drugs.
"DCF's strong appreciation of the subtleties of the industry
landscape in which the Company operates created significant value
to all shareholders throughout the entire sale process. Their
process identified the most reliable buyer but more importantly,
the most knowledgeable and best suited partner for the Company's
next phase of growth. It was a pleasure working with their
team," said Jonathan Lewis, managing
principal and partner for Sheridan Legacy Group.
"Advising Diamondback Drugs for the second time marks the fifth
deal we've closed in this niche space during the past 24 months,"
said Dave Vorhoff, managing director
for Deloitte Corporate Finance LLC. "Since making its
investment in the Company in 2012, Sheridan
Legacy actively worked with Diamondback Drugs' management
team to enhance the value proposition to veterinarians and pet
owners, yielding results that attracted a number of potential
suitors for the business."
About Diamondback Drugs of Delaware, LLC
Diamondback Drugs is a national specialty veterinary pharmacy,
serving veterinary clinics, veterinary hospitals, aquariums and
zoos, research institutions, and individual animal owners.
Diamondback Drugs' products are tailor-made for the specific
pet-patient in need, allowing for greater flexibility in treatment.
Since 2001, Diamondback Drugs' products have been treating
veterinary patients across the nation for a variety of ailments
using a multitude of dosage forms including injectables, tablets,
and chewables. For more information about Diamondback Drugs and its
products, visit www.diamondbackdrugs.com.
About Sheridan Legacy Group, LLC
Founded in 2012, Sheridan Legacy Group, LLC is a private equity
investment firm based in Chicago,
Illinois. Sheridan Legacy
prefers to invest in small and medium sized companies to partner
with exceptional managers, entrepreneurs, and owners.
Industry sectors of interest for Sheridan
Legacy include Healthcare and Consumer products. More
information about Sheridan Legacy
can be found at www.sheridanlegacy.com.
About Tailwind Capital
Founded in 2003, Tailwind Capital is a leading private equity
firm focused on making control-oriented investments in the lower
end of the middle market and transforming businesses through
organic growth, acquisitions, and operational and strategic
improvements. Tailwind targets niche businesses in the Healthcare,
Business and Communications Services sectors. For further
information, please visit: www.tailwind.com.
About Deloitte Corporate Finance LLC
Deloitte Corporate Finance LLC (DCF) provides strategic advisory
services and M&A advice that help corporate, entrepreneurial
and private equity clients create and act upon opportunities for
liquidity, growth and long-term advantage. With an in-depth
understanding of the marketplace and access to a global network of
investment bankers, we help clients confidently pursue strategic
transactions in both domestic and global markets. DCF, together
with the Corporate Finance Advisory practices within the Deloitte
Touche Tohmatsu Limited network of member firms, include in excess
of 1,900 professionals, who work collaboratively across 150
international locations. With our significant experience providing
investment banking services across key industries, we are able to
offer our clients solutions that help them to achieve their
strategic objectives. For more information, visit
www.investmentbanking.deloitte.com.
Prior engagement performance is no guarantee of future
performance and may not be representative of the experience of
other clients. This communication is for informational purposes
only and is not intended as an offer or solicitation for the
purchase or sale of a security.
Deloitte Corporate Finance LLC, an SEC registered broker-dealer
and member of FINRA and SIPC, is an indirect wholly-owned
subsidiary of Deloitte Financial Advisory Services LLP and
affiliate of Deloitte Transactions and Business Analytics LLP.
Investment banking products and services within the United States are offered exclusively
through Deloitte Corporate Finance LLC. For more information, visit
www.investmentbanking.deloitte.com. Please see
www.deloitte.com/us/about for a detailed description of the legal
structure of Deloitte LLP and its subsidiaries. Certain services
may not be available to attest clients under the rules and
regulations of public accounting.
Logo -
http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/deloitte-corporate-finance-llc-advises-diamondback-drugs-of-delaware-llc-in-its-sale-to-tailwind-capital-300012622.html
SOURCE Deloitte